P‑PSMA‑101 CAR‑T Therapy in Advanced Prostate Cancer: Early Results from a Phase 1 Trial

/in , , /by

P‑PSMA‑101 is an experimental CAR‑T cell therapy being tested in men with metastatic castration‑resistant prostate cancer (mCRPC) who have already received multiple standard treatments (up to 10 before enrollment). In the phase 1 trial, 33 men with heavily pretreated mCRPC received P‑PSMA‑101, an autologous PSMA‑targeted CAR‑T product enriched in stem‑cell‑like memory T cells and engineered […]

Read more

Complete Response to Pembrolizumab in a Metastatic, Castration‑Resistant Prostate Cancer Survivor

/in /by

A remarkable case published in Annals of Internal Medicine: Clinical Cases highlights a man with metastatic, castration‑resistant prostate cancer who achieved a complete and durable response to pembrolizumab after exhausting multiple standard therapies. The patient had previously received abiraterone‑based treatment followed by chemotherapy, and then olaparib, all of which he had progressed on, leaving him […]

Read more

Phase 1/2 PARTHENON Trial: AZD4956 Targets HRD in Advanced Prostate Cancer

/in , , , /by

The PARTHENON trial tests AZD4956, an experimental oral drug that blocks SMARCA2, a protein helping cancer cells rearrange their DNA to keep growing. In tumors already “weak” at fixing DNA damage due to homologous recombination deficiency (HRD), shutting down SMARCA2 creates a double hit: cells can’t remodel chromatin or repair errors, leading to collapse. This […]

Read more

Phase 1 Trial for SYS6043: A New Antibody-Drug Conjugate Targeting B7-H3

/in , , /by

SYS6043 is a new type of antibody-drug conjugate, or ADC. It zeroes in on B7-H3, a protein that is expresse by advanced tumors but almost not at all on healthy cells. The antibody part sticks to B7-H3, gets pulled inside the cancer cell, and releases a topoisomerase I inhibitor that breaks the cell’s DNA and […]

Read more

HER2 FPBMC Therapy in the AM006 Phase 1/2 Trial for Metastatic Prostate Cancer

/in , , , /by

The AM006 clinical trial, tests HER2 FPBMC anti-CD3 x anti-HER2 bispecific antibody (HER2Bi)-armed activated T cells, in patients with HER2-positive metastatic prostate and breast cancer. For prostate cancer patients, this targets the 20-30% of metastatic cases overexpressing HER2, offering a fresh immune-based option after standard therapies fail. HER2 FPBMC starts with a simple blood draw […]

Read more

Capivasertib + Abiraterone in CAPItello-281: Promising rPFS in PTEN-Deficient mHSPC

/in , , /by

The phase 3 trial CAPItello-281, has delivered compelling evidence that capivasertib combined with abiraterone could transform treatment for PTEN-deficient metastatic hormone-sensitive prostate cancer (mHSPC), a subtype affecting a substantial portion of advanced cases. In this double-blind study, 1012 patients with PTEN deficiency (defined rigorously as 90% or more viable malignant cells showing no cytoplasmic staining […]

Read more

Final PEACE-3 Trial Data: Radium-223 + Enzalutamide Extends Survival by 5.6 Months in Bone mCRPC.

/in , , /by

Radium-223 plus enzalutamide significantly boosts survival for men with metastatic castration-resistant prostate cancer (mCRPC) and bone metastases, according to final results from the Phase 3 PEACE-3 trial  presented at ASCO GU 2026. In this study of 446 patients with at least two bone metastases who were asymptomatic or only mildly symptomatic, adding six infusions of […]

Read more

Phase 2 Trial of Cu-64 SAR-bisPSMA Doubles Prostate Lesion Detection

/in , , /by

64Cu-SAR-bisPSMA represents a next-generation PSMA-targeted PET imaging agent for prostate cancer, demonstrating superior lesion and patient detection in the Phase 2 Co-PSMA trial announced in February 2026. In this head-to-head study of 50 patients with biochemical recurrence (BCR) after prostatectomy (PSA 0.2-0.75 ng/mL), Cu-64 SAR-bisPSMA more than doubled mean lesions per patient at 1.26 (63 […]

Read more